Evidence map›Paper›PMID 28402699›Full record

ArticleAutophagy2017

Inhibition of retrograde transport modulates misfolded protein accumulation and clearance in motoneuron diseases.

Riccardo Cristofani, Valeria Crippa, Paola Rusmini, Maria Elena Cicardi, Marco Meroni, Nausicaa V Licata, Gessica Sala, Elisa Giorgetti, Christopher Grunseich, Mariarita Galbiati and 5 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Autophagy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03693781 (Colchicine for Amyotrophic Lateral Sclerosis), which is not on this map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03693781 phase2completednot on this mapstarted 2019, after this paper: background citation

Colchicine for Amyotrophic Lateral Sclerosis: a Phase II, Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial

TypeinterventionalSponsorAzienda Ospedaliero-Universitaria di ModenaRan2019 to 2023Enrolled54ConditionsAmyotrophic Lateral SclerosisArmsColchicine 1 MG Oral Tablet, Placebo Oral Tablet
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Protein homeostasis in the aged and diseased heart.The journal of cardiovascular aging · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Multiple roles for the cytoskeleton in ALS.Experimental neurology · 2022
    Review
  15. Review
  16. Article
  17. Article
  18. Valosin Containing Protein (VCP): A Multistep Regulator of Autophagy.International journal of molecular sciences · 2022
    Review
  19. Article
  20. Protein clearance strategies for disease intervention.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Riccardo Cristofania Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative , Università degli Studi di Milano , Milano , Italy.ORCID http://orcid.org/0000-0003-2719-846X
Valeria Crippaa Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative , Università degli Studi di Milano , Milano , Italy.ORCID http://orcid.org/0000-0002-3058-5711
Paola Rusminia Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative , Università degli Studi di Milano , Milano , Italy.ORCID http://orcid.org/0000-0001-9989-0733
Maria Elena Cicardia Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative , Università degli Studi di Milano , Milano , Italy.ORCID http://orcid.org/0000-0001-9490-303X
Marco Meronia Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative , Università degli Studi di Milano , Milano , Italy.ORCID http://orcid.org/0000-0001-6682-4799
Nausicaa V Licataa Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative , Università degli Studi di Milano , Milano , Italy.ORCID http://orcid.org/0000-0003-0750-0692
Gessica Salac School of Medicine and Surgery, NeuroMI Milan Center for Neuroscience , University of Milano-Bicocca , Italy.ORCID http://orcid.org/0000-0003-3573-7523
Elisa Giorgettia Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative , Università degli Studi di Milano , Milano , Italy.ORCID http://orcid.org/0000-0001-7960-0663
Christopher Grunseichd Neurogenetics Branch , National Institute of Neurological Disorders and Stroke, NIH , Bethesda , MD , USA.ORCID http://orcid.org/0000-0003-4994-2472
Mariarita Galbiatia Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative , Università degli Studi di Milano , Milano , Italy.ORCID http://orcid.org/0000-0003-3250-5591
Margherita Piccolellaa Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative , Università degli Studi di Milano , Milano , Italy.ORCID http://orcid.org/0000-0002-5130-1116
Elio Messia Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative , Università degli Studi di Milano , Milano , Italy.ORCID http://orcid.org/0000-0002-9515-1463
Carlo Ferraresec School of Medicine and Surgery, NeuroMI Milan Center for Neuroscience , University of Milano-Bicocca , Italy.ORCID http://orcid.org/0000-0002-7499-6600
Serena Carrae Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze , Università degli Studi di Modena e Reggio Emilia, Centro di Neuroscienze e Neurotecnologie , Modena , Italy.ORCID http://orcid.org/0000-0003-0939-0140
Angelo Polettia Sezione di Biomedicina ed Endocrinologia, Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative , Università degli Studi di Milano , Milano , Italy.ORCID http://orcid.org/0000-0002-8883-0468
University of Milan · ITUniversity of Milano-Bicocca · ITNational Institute of Neurological Disorders and Stroke · USUniversity of Modena and Reggio Emilia · IT

Funding

Studies of Hereditary Neurological Disease: Disease MechanismsZIANS003038 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI FISCHBECK, KENNETH · 2009 to 2023
$19.5M
Telethon GGP14039Telethon GGP15001
6 · The paper itself

Abstract

Motoneuron diseases, like spinal bulbar muscular atrophy (SBMA) and amyotrophic lateral sclerosis (ALS), are associated with proteins that because of gene mutation or peculiar structures, acquire aberrant (misfolded) conformations toxic to cells. To prevent misfolded protein toxicity, cells activate a protein quality control (PQC) system composed of chaperones and degradative pathways (proteasome and autophagy). Inefficient activation of the PQC system results in misfolded protein accumulation that ultimately leads to neuronal cell death, while efficient macroautophagy/autophagy-mediated degradation of aggregating proteins is beneficial. The latter relies on an active retrograde transport, mediated by dynein and specific chaperones, such as the HSPB8-BAG3-HSPA8 complex. Here, using cellular models expressing aggregate-prone proteins involved in SBMA and ALS, we demonstrate that inhibition of dynein-mediated retrograde transport, which impairs the targeting to autophagy of misfolded species, does not increase their aggregation. Rather, dynein inhibition correlates with a reduced accumulation and an increased clearance of mutant ARpolyQ, SOD1, truncated TARDBP/TDP-43 and expanded polyGP C9ORF72 products. The enhanced misfolded protein clearance is mediated by the proteasome, rather than by autophagy and correlates with the upregulation of the HSPA8 cochaperone BAG1. In line, overexpression of BAG1 increases the proteasome-mediated clearance of these misfolded proteins. Our data suggest that when the misfolded proteins cannot be efficiently transported toward the perinuclear region of the cells, where they are either degraded by autophagy or stored into the aggresome, the cells activate a compensatory mechanism that relies on the induction of BAG1 to target the HSPA8-bound cargo to the proteasome in a dynein-independent manner.

Indexed as

Protein FoldingAnimalsAutophagyBiological TransportCell DifferentiationDNA-Binding ProteinsDyneinsGene SilencingHSP20 Heat-Shock ProteinsHumansInduced Pluripotent Stem CellsMiceMotor Neuron DiseaseMotor NeuronsPC12 CellsPeptidesBCL2-associated athanogene 1 proteinDNA-Binding ProteinsDyneinsHSP20 Heat-Shock ProteinsPeptidespolyglutamineProteasome Endopeptidase ComplexRNA, Small InterferingSuperoxide DismutaseTranscription FactorsUbiquitinaggregationamyotrophic lateral sclerosisautophagyBAG1BAG3HSPB8misfolded proteinproteasomeprotein quality control

Identifiers

PMID28402699
PMCPMC5584856
OpenAlexW2607295011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.